Literature DB >> 1565144

Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms.

D Malkin1, K W Jolly, N Barbier, A T Look, S H Friend, M C Gebhardt, T I Andersen, A L Børresen, F P Li, J Garber.   

Abstract

BACKGROUND: Acquired mutations in the p53 tumor-suppressor gene have been detected in several human cancers, including colon, breast, and lung cancer. Inherited mutations (transmitted through the germline) of this gene can underlie the Li-Fraumeni syndrome, a rare familial association of breast cancer in young women, childhood sarcomas, and other malignant neoplasms. We investigated the possibility that p53 mutations in the germline are associated with second primary cancers that arise in children and young adults who would not be considered as belonging to Li-Fraumeni families.
METHODS: Genomic DNA was extracted from the blood leukocytes of 59 children and young adults with a second primary cancer. The polymerase chain reaction, in combination with denaturant-gel electrophoresis and sequencing, was used to identify p53 gene mutations.
RESULTS: Mutations of p53 that changed the predicted amino acid sequence were identified in leukocyte DNA from 4 of the 59 patients (6.8 percent). In three cases, the mutations were identical to ones previously found in the p53 gene. The fourth mutation was the first germline mutation to be identified in exon 9, at codon 325. Analysis of leukocyte DNA from close relatives of three of the patients indicated that the mutations were inherited, but cancer had developed in only one parent at the start of the study.
CONCLUSIONS: These findings identify an important subgroup of young patients with cancer who carry germline mutations in the p53 tumor-suppressor gene but whose family histories are not indicative of the Li-Fraumeni syndrome. The early detection of such mutations would be useful not only in treating these patients, but also in identifying family members who may be at high risk for the development of tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1565144     DOI: 10.1056/NEJM199205143262002

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  60 in total

Review 1.  Cancer risks from germline p53 mutations.

Authors:  T Frebourg; S H Friend
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

3.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

Review 4.  Next-generation sequencing for inherited breast cancer risk: counseling through the complexity.

Authors:  Irene R Rainville; Huma Q Rana
Journal:  Curr Oncol Rep       Date:  2014-03       Impact factor: 5.075

5.  Simultaneous adrenocortical carcinoma and ganglioneuroblastoma in a child with Turner syndrome and germline p53 mutation.

Authors:  E K Pivnick; W L Furman; G V Velagaleti; J J Jenkins; N A Chase; R C Ribeiro
Journal:  J Med Genet       Date:  1998-04       Impact factor: 6.318

Review 6.  The p53 family and programmed cell death.

Authors:  E C Pietsch; S M Sykes; S B McMahon; M E Murphy
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

7.  Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Authors:  L Diller; E Sexsmith; A Gottlieb; F P Li; D Malkin
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers.

Authors:  A Ziegler; D J Leffell; S Kunala; H W Sharma; M Gailani; J A Simon; A J Halperin; H P Baden; P E Shapiro; A E Bale
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

Review 9.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

10.  Absence of p53 mutation in Japanese patients with malignant thyroid lymphoma.

Authors:  K Iyota; K Takeda; F Matsuzuka; T Okabayashi; S Morita; K Kuma; K Hashimoto
Journal:  J Endocrinol Invest       Date:  1994-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.